Durvalumab is an anti-PD-L1 monoclonal antibody that blocks this interaction, reactivating T cells so they can recognize and attack the cancer cells. This approach boosts the body’s immune response against the tumor and is particularly effective in patients with stage III NSCLC who have not shown disease progression after chemotherapy and radiation. Here, CD274 is linked to neoplasm.